JaLCDOI 10.18926/AMO/54603
FullText URL 70_5_409.pdf
Author Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune|
Abstract Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
Keywords Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type Clinical Study Protocols
Published Date 2016-10
Publication Title Acta Medica Okayama
Volume volume70
Issue issue5
Publisher Okayama University Medical School
Start Page 409
End Page 412
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27777437
Web of Sience KeyUT 000388098700014
Author Soga, Yoshihiko| Maeda, Yoshinobu| Tanimoto, Mitsune| Ebinuma, Takayuki| Maeda, Hiroshi| Takashiba, Shogo|
Published Date 2013-02
Publication Title Supportive Care in Cancer
Volume volume21
Issue issue2
Content Type Journal Article
Author Ebinuma, Takayuki| Soga, Yoshihiko| Sato, Takamaro| Matsunaga, Kazuyuki| Kudo, Chieko| Maeda, Hiroshi| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo|
Published Date 2014-06
Publication Title Supportive Care in Cancer
Volume volume22
Issue issue6
Content Type Journal Article
Sort Key 10
Title Alternative An investigator initiated phase II clinical trial of tamibarotene (AM80G) for chronic graft-versus-host disease
FullText URL 127_133.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu|
Keywords 臨床研究中核病院 慢性GVHD タミバロテン 同種造血幹細胞移植 Th17
Note 特集(Feature Articles)
Publication Title 岡山医学会雑誌
Published Date 2015-08-03
Volume volume127
Issue issue2
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 133
End Page 137
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
Related Url isVersionOf https://doi.org/10.4044/joma.127.133
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.127.133
NAID 文ID(NAID) 130005096255
Eprints Journal Name joma
References 1) Teshima T, Maeda Y, Ozaki K : Regulatory T cells and IL-17-producing cells in graft-versus-host disease. Immunotherapy (2011) 3, 833-852. 2) Nishimori H, Maeda Y, Teshima T, Sugiyama H, Kobayashi K, Yamasuji Y, Kadohisa S, Uryu H, Takeuchi K, Tanaka T, Yoshino T, Iwakura Y, et al. : Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood (2012) 119, 285-295. 3) Nishimori H, Maeda Y, Tanimoto M : Chronic graft-versus-host disease : disease biology and novel therapeutic strategies. Acta Med Okayama (2013) 67, 1-8. 4) Ferrara JL, Antin JH : The pathophysiology of graft-vs-host disease ; in Thomas'Hematopoietic Cell Transplantation Malden, Blume KG, Forman SJ, Appelbaum FR (eds), Blackwell Science, MA, USA (2004) pp353-368. 5) Martin PJ, Inamoto Y, Carpenter PA, Lee SJ, Flowers ME : Treatment of chronic graft-versus-host disease : Past, present and future. Korean J Hematol (2011) 46, 153-163. 6) Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, et al. : Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 365、2055-2066. 7) Hashimoto Y, Shudo K : Retinoids and their nuclear receptors. Cell Biol Rev (1991) 25, 209-235. 8) Hashimoto Y : Retinobenzoic acids and nuclear retinoic acid receptors. Cell Struct Funct (1991) 16, 113-123. 9) Hashimoto Y, Kagechika H, Kawachi E, Fukasawa H, Saito G, Shudo K : Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. J Cancer Res Clin Oncol (1995) 121, 696-698. 10) Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K : Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem (1988) 31, 2182-2192. 11) Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, et al. : Tamibarotene as maintenance therapy for acute promyelocytic leukemia : results from a randomized controlled trial. J Clin Oncol (2014) 32, 3729-3735. 12) Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R : Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood (1997) 90, 967-973. 13) Nagai H, Matsuura S, Bouda K, Takaoka Y, Wang T, Niwa S, Shudo K : Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology (1999) 58, 101-112. 14) Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H : Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (2007) 317, 256-260. 15) Okamoto S, Fujiwara H, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Yoshimura A, Tanimoto M, Maeda Y : Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-gamma/IL-17-producing cells. J Immunol (2015) 194, 1357-1363. 16) Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, Martin PJ : Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 121, 2340-2346.
Author Iwatani, Kayoko| Takata, Katsuyoshi| Sato, Yasuharu| Miyata-Takata, Tomoko| Iwaki, Noriko| Cui, Wei| Sawada-Kitamura, Seiko| Sonobe, Hiroshi| Tamura, Maiko| Saito, Katsuhiko| Miyatani, Katsuya| Yamasaki, Rie| Yamadori, Ichiro| Fujii, Nobuharu| Terasaki, Yasushi| Maeda, Yoshinobu| Tanimoto, Mitsune| Nakamura, Naoya| Yoshino, Tadashi|
Published Date 2014-07
Publication Title Human Pathology
Volume volume45
Issue issue7
Content Type Journal Article
Author Sugiyama, Haruko| Maeda, Yoshinobu| Nishimori, Hisakazu| Yamasuji, Yoshiko| Matsuoka, Ken-ichi| Fujii, Nobuharu| Kondo, Eisei| Shinagawa, Katsuji| Tanaka, Takehiro| Takeuchi, Kengo| Teshima, Takanori| Tanimoto, Mitsune|
Published Date 2014-02
Publication Title Biology of Blood and Marrow Transplantation
Volume volume20
Issue issue2
Content Type Journal Article
Author Sonoi, Norihiro| Soga, Yoshihiko| Maeda, Hiroshi| Ichimura, Koichi| Yoshino, Tadashi| Aoyama, Kazutoshi| Fujii, Nobuharu| Maeda, Yoshinobu| Tanimoto, Mitsune| Logan, Richard| Raber-Durlacher, Judith| Takashiba, Shogo|
Published Date 2012-07
Publication Title Odontology
Volume volume100
Issue issue2
Content Type Journal Article
Sort Key 13
Title Alternative Molecular targeted therapy in myeloma and lymphoma
FullText URL 126_143.pdf
Author Saeki, Kyosuke| Maeda, Yoshinobu| Tanimoto, Mitsune|
Keywords 骨髄腫 リンパ腫 分子標的治療薬
Note 特集 (Feature Article)
Publication Title 岡山医学会雑誌
Published Date 2014-08-01
Volume volume126
Issue issue2
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 143
End Page 150
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.126.143
NAID 130004685266
Eprints Journal Name joma
References 1) Cartron G, Watier H, Golay J, Solal-Celigny P : From the bench to the bedside : ways to improve rituximab efficacy. Blood (2004) 104, 2635-2642. 2) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, et al. : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 346, 235-242. 3) Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O : Rituximab maintenance for the treatment of patients with follicular lymphoma : systematic review and meta-analysis of randomized trials. J Natl Cancer Inst (2009) 101, 248-255. 4) Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, et al. : Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 23, 4079-4088. 5) Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, et al. : High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol (2005) 23, 7013-7023. 6) Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, et al. : Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma : results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol (2005) 23, 1984-1992. 7) Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, et al. : Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 106, 1569-1580. 8) Cheson BD : Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol (2010) 28, 3525-3530. 9) Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, et al. : First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma : results of a phase 1/2 trial. Blood (2008) 111, 5486-5495. 10) Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A ; Hx-CD20-406 Study Investigators : Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab : results from the phase 2 international study. Blood (2011) 118, 5126-5129. 11) Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, et al. : Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 30, 2183-2189. 12) Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL,et al. : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma : results of a phaseⅡstudy. J Clin Oncol (2012) 30, 2190-2196. 13) Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, et al. : Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma : results of a phase I study. J Clin Oncol (2010) 28, 2085-2093. 14) Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, et al. : Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : a multicenter phaseⅡstudy. J Clin Oncol (2012) 30, 837-842. 15) Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, et al. : Multicenter PhaseⅡStudy of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. J Clin Oncol (2014) 32, 1157-1163. 16) Viardot A, Goebeler M, Nopponey R, Krause SW, Kallert S, Ferstl B, Mackensen A, Rupertus K, Soekler M, Kanz L, Knop S, Topp MS, et al. : Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. ASH Annu Meet Abstr (2011) 188, 1637. 17) Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA : Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : long-term follow-up of a phase 1/2 study. Blood (2004) 103, 4429-4431. 18) Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, et al. : Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 23, 5044-5051. 19) Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, et al. : Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 31, 88-94. 20) Coutre SE, Leonard JP, Furman RR, Barrientos JC, Sven de Vos, Flinn IW, Schreeder MT, Wagner-Johnston ND, Sharman OP, Boyd TE, Fowler NH, Holes LM, et al. : Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) : results from a phase I study. ASH Ann Meet Abstr (2012) 120, 191. 21) Furman RR, Barrientos JC, Sharman JP, Sven De Vos, Leonard J, Coutre SE, Schreeder MT, Wagner-Johnston ND, Boyd TE, Fowler NH, Flinn IW, Boccia RV, et al. : A phaseⅠ/Ⅱstudy of the selective phosphatidylinositol 3-kinase-delta (PI3 Kdelta) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol (2012) 30, S6518. 22) Guidetti A, Viviani S, Marchianò A, Dodero A, Farina L, Locatelli S, Russo D, Bulian P, Sorasio R, Nicola MD, Giordano L, Corradini P, et al. : Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas : final results of a phaseⅡtrial. ASH Annu Meet Abstr (2012) 120, 3679. 23) Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, et al. : Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 27, 3822-3829. 24) Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, et al. : Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes : The University of Chicago phase II consortium. J Clin Oncol (2010) 28, 4740-4746. 25) Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, et al. : PhaseⅡstudy of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 25, 1741-1746. 26) Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, Tilly H, Raemaekers J, van't Veer MB, Milpied N, Cartron G, Pezzutto A, et al. : A phaseⅡstudy of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol (2008) 19, 247-253. 27) Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK : High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma : results of a global phase 3b expanded access program. Br J Haematol (2009) 144, 169-175. 28) Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, et al. : A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 120, 2817-2825. 29) Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, et al. : Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 26, 4952-4957. 30) Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, et al. : Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma : a phase 1/2 clinical trial. Lancet Oncol (2012) 13,716-723. 31) Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M : Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 25, 3109-3115. 32) Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, et al. : Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 117, 5827‒5834. 33) Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T, Tobinai K : Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci (2012) 103, 1290-1295. 34) Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, et al. : Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2010) 115, 2578-2585.
Title Alternative Molecular targeted therapies in leukemia
FullText URL 126_49.pdf
Author Maeda, Yoshinobu| Tanimoto, Mitsune|
Keywords 白血病 分子標的薬 チロシンキナーゼ阻害薬
Note 特集 (Feature Article)
Publication Title 岡山医学会雑誌
Published Date 2014-04-01
Volume volume126
Issue issue1
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 49
End Page 54
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
Related Url http://www.okayama-u.ac.jp/user/oma/
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.126.49
Sort Key 10
Eprints Journal Name joma
References 1) Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J : Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood (2006) 108, 1835-1840. 2) Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, et al. : Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2012) 119, 1123-1129. 3) Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M : Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344, 1038-1042. 4) Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, et al. : High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2006) 24, 460-466. 5) Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, et al. : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 369, 1783-1796. 6) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, et al. : A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 366, 799-807. 7) Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, et al. : JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 366, 787-798. 8) Byrd JC, Furman RR, Coutre SE, Flinn ZW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, et al. : Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 369, 32-42. 9) O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, et al. : Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : an open-label, multicentre, phase 1b/2 trial. Lancet Oncol (2014) 15, 48-58. 10) Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T : BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 366, 2038-2040. 11) Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, et al. : Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B. J Clin Oncol (2002) 20, 2429-2440. 12) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, et al. : Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol (2009) 10, 223-232.
Author 杉浦 裕子| 曽我 賢彦| 前田 嘉信|
Published Date 2010-09-01
Publication Title 造血細胞移植now&future
Volume volume20
Content Type Article
Author Hayashi, Eiko| Takata, Katsuyoshi| Sato, Yasuharu| Tashiro, Yukie| Tachiyama, Yoshiro| Sawada-Kitamura, Seiko| Hiramatsu, Yasushi| Sugiguchi, Shun| Nose, Soichiro| Hirokawa, Mitsuyoshi| Ando, Midori| Abd Mader, Lamia| Maeda, Yoshinobu| Tanimoto, Mitsune| Yoshino, Tadashi|
Published Date 2013-09
Publication Title Human Pathology
Volume volume44
Issue issue9
Content Type Journal Article
JaLCDOI 10.18926/AMO/51868
FullText URL 67_5_319.pdf
Author Murakawa, Kiminaka| Sato, Tomoaki| Maeda, Yoshinobu| Kitamura, Yoshihisa| Tanimoto, Mitsune| Sendo, Toshiaki|
Abstract Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.
Keywords beclomethasone intestinal graft-versus-host disease enteric-coated capsule in-hospital formulation
Amo Type Case Report
Published Date 2013-10
Publication Title Acta Medica Okayama
Volume volume67
Issue issue5
Publisher Okayama University Medical School
Start Page 319
End Page 324
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 24145732
Web of Sience KeyUT 000325836100006
Author Takata, Katsuyoshi| Sato, Yasuharu| Nakamura, Naoya| Tokunaka, Mami| Miki, Yukari| Kikuti, Yara Yukie| Igarashi, Kazuhiko| Ito, Etsuro| Harigae, Hideo| Kato, Seiichi| Hayashi, Eiko| Oka, Takashi| Hoshii, Yoshinobu| Tari, Akira| Okada, Hiroyuki| Mohamado, ABD Alkader Lamia| Maeda, Yoshinobu| Tanimoto, Mitsune| Kinoshita, Tomohiro| Yoshino, Tadashi|
Published Date 2013-08-01
Publication Title 岡山医学会雑誌
Volume volume125
Issue issue2
Content Type Journal Article
JaLCDOI 10.18926/AMO/49251
FullText URL 67_1_1.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune|
Abstract Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.
Keywords chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory
Amo Type Review
Published Date 2013-02
Publication Title Acta Medica Okayama
Volume volume67
Issue issue1
Publisher Okayama University Medical School
Start Page 1
End Page 8
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2013 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 23439503
Web of Sience KeyUT 000316829900001
Author Soga, Yoshihiko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Maeda, Hiroshi| Nishimura, Fusanori| Takashiba, Shogo|
Published Date 2011-07
Publication Title Supportive Care in Cancer
Volume volume19
Issue issue7
Content Type Journal Article
Author Takahashi, Kanayo| Soga, Yoshihiko| Murayama, Yumeno| Udagawa, Mika| Nishimoto, Hitomi| Sugiura, Yuko| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo|
Published Date 2010-01
Publication Title Supportive Care in Cancer
Volume volume18
Issue issue1
Content Type Journal Article
Author Soga, Yoshihiko| Yamasuji, Yoshiko| Kudo, Chieko| Matsuura-Yoshimoto, Kaori| Yamabe, Kokoro| Sugiura, Yuko| Maeda, Yoshinobu| Ishimaru, Fumihiko| Tanimoto, Mitsune| Nishimura, Fusanori| Takashiba, Shogo|
Published Date 2009-05
Publication Title Supportive Care in Cancer
Volume volume17
Issue issue5
Content Type Journal Article
Author Soga, Yoshihiko| Sugiura, Yuko| Takahashi, Kanayo| Nishimoto, Hitomi| Maeda, Yoshinobu| Tanimoto, Mitsune| Takashiba, Shogo|
Published Date 2011-02
Publication Title Supportive Care in Cancer
Volume volume19
Issue issue2
Content Type Journal Article
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune|
Published Date 2012-12-03
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue3
Content Type Journal Article
Author Asakura, Shoji| Hashimoto, Daigo| Takashima, Shuichiro| Sugiyama, Haruko| Maeda, Yoshinobu| Akashi, Koichi| Tanimoto, Mitsune| Teshima, Takanori|
Published Date 2012-04-01
Publication Title 岡山医学会雑誌
Volume volume124
Issue issue1
Content Type Journal Article